Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, the industry analysis specialist, has released its new report, "Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the global osteoarthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global OA therapeutics market was worth $4.4 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 3.8% to reach $5.9 billion by 2018. The current treatment options for OA offer only symptomatic relief and are primarily dominated by generics. There are no disease modifying osteoarthritis drugs (DMOAD) currently approved in the OA therapeutics market and the late stage pipeline also lacks DMOADs except SMC021. Owing to all the above factors the OA therapeutics market is expected to show slow growth till 2018.
The report provides information on the key drivers and challenges of the osteoarthritis therapeutics market. Its scope includes -
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
Pipeline analysis data providing analysis of the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for osteoarthritis fall under major therapeutic classes such as stem cell therapy, cyclooxygenase (COX) inhibitor, cathepsin inhibitors, opioid receptor agonist, anti-nerve growth factor (NGF) inhibitor, transient receptor potential vanilloid-1 (TRPV-1) antagonists, cyclooxygenase inhibiting nitric oxide donor, phosphodiesterase inhibitor and calcitonin receptor agonist.
Analysis of current and future competition in the global osteoarthritis market is provided. Key market players covered are BioDelivery Sciences International, Cephalon Inc, Iroko Pharmaceuticals, LLC, Novartis AG, SantoSolve AS and Winston Pharmaceuticals, Inc.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis therapeutics market.
Analysis of key recent licensing and partnership agreements in osteoarthritis therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global osteoarthritis therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What's the next big thing in the global osteoarthritis therapeutics market landscape? - Identify, understand and capitalize.
Figure 22: OA Therapeutics Market, Drivers and Restraints 2011 34
Figure 23: Opportunity and Unmet Need in the OA Therapeutics Market, 2011 35
Figure 24: OA Therapeutics - Strategic Competitor Assessment, 2011 36
Figure 25: OA Therapeutics - Pipeline by Phase of Clinical Development, 2011 42
Figure 26: OA Therapeutics Pipeline - DMOAD versus Symptomatic Relief, 2011 42
Figure 27: OA Market - Clinical Pipeline by Mechanism of Action, 2011 46
Figure 28: Technology Trends Analytical Framework of the OA Pipeline, 2011 48
Figure 29: Technology Trends Analytical Framework of the OA Pipeline - Description, 2011 49
Figure 30: OA Therapeutics - Clinical Trials by Country, 2011 53
Figure 31: OA Therapeutics - Clinical Trials by Phase, 2011 54
Figure 32: OA Therapeutics - Clinical Trials by Status, 2011 55
Figure 33: OA Therapeutics - Overall Sponsors, 2011 56
Figure 34: OA Therapeutics - Prominent Sponsors, 2011 57
Figure 35: OA Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 58
Figure 36: Implications for Future Market Competition in the Osteoarthritis Therapeutics Market, 2011 59
Figure 37: OA Therapeutics Market - Clinical Pipeline by Company , 2011 60
Figure 38: GlobalData Market Forecasting Model 77
Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 published by GlobalData in November 30, 2011. This report consists of Pages: 80 and the price starts from US $ 3500.
Osteoarthritis Therapeutics - Lack of Availability of Disease Modifying Osteoarthritis Drugs Slows Market Growth
November 8th, 2011
Global Information, Inc. presents "Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" by GlobalData.
Osteoarthritis (OA) is the most common type of arthritis and is a leading cause of disability globally. It is also known as degenerative joint disease, hypertrophic arthritis and degenerative arthritis. It is a chronic, progressive degenerative joint disease characterized by gradual destruction of articular cartilage, hypertrophy of bone at the margins, subchondral sclerosis and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and a loss of movement. Affected joints can also cause swelling, warmth, creaking and stiffness.
OA affects people of all ages but is most commonly prevalent in elderly and middle-aged people. The chance of developing OA increases with age due to changes in the musculoskeletal system. More women suffer from it than men. The joints affected and the severity of the disease is related to risk factors such as joint injury, obesity, genetics, and anatomical factors that affect joint mechanics. The joints of knees, hips and spine are affected more than the shoulder, elbow and wrist.
Slow Growth Esimated for the Global Osteoarthritis Market
The OA therapeutics market is expected to grow at a CAGR of 3.8% to reach $5.9 billion in 2018 from $4.4 billion in 2010. The US market is expected to remain the biggest contributor to the global revenues in 2018.
The OA market lacks disease modifying OA drugs. No disease modifying agent is approved and there are none in the late stage of clinical development. The pipeline is dominated by drugs that offer symptomatic relief and there are no disease modifying drugs which may alter the disease progression the OA. Owing to these factors the OA therapeutics market is expected to show slow growth until 2018.
Patent Expiry of Major Drugs to Further Slow the Market
The current market for OA therapeutics is largely dominated by generics which have a low annual cost of therapy. Further branded products such as Cymbalta and Celebrex will lose their patent exclusivities by the end of 2013 and 2014. The entry of generic versions of these drugs will further reduce the cost of therapy. Reduction in the cost of therapy will hamper the growth of the market during the forecast period.
Limited Treatment options lead to a Significant Unmet Need in the OA Therapeutics Market
Current treatment options for OA are limited. OA has no known cure and the currently marketed therapies are intended to relieve symptoms and prevent exacerbation. There is currently no drug which can halt or reverse disease progression. Hence there is a significant unmet need for effective disease modifying therapies that target the underlying pathophysiology of OA. There is a critical need for compounds that not only halt the inflammation but reverse the progressive loss of cells and tissue leading to the loss of joint function and improve the overall quality of life of the OA patients.
The current market lacks DMOADs and there exists a significant unmet need in OA treatment. There are no DMOADs in the late stage of the pipeline except SMC021. SMC02 however has not shown promising results in Phase III clinical trials and failed to meet the first of its three co-primary endpoints. The significant unmet need is expected to continue during the forecast period. With no disease modifying drugs available for OA patients they are forced to depend on symptomatic relief medications.
Scope for Entrants with Better Efficacy and Safety Profiles
Current treatments for OA offer only symptomatic relief and lack the ability to control the disease progression which is a leading cause of disability. No disease modifying agent is currently approved for the treatment of OA. The management of OA involves nonpharmacologic modes of therapy as well as pharmacologic agents.
The OA therapeutics market is underserved by the currently marketed drugs as no drug can provide a cure for the disease. The market offers huge potential for new entrants who can develop drugs that halt or reverse the disease progression and simultaneously offer a good efficacy and safety profile. There is also a huge potential for novel therapies which can offer better symptomatic relief. New formulations of approved drugs will also capture a significant market share if they can demonstrate a convenient route of administration and schedule, enhanced long term efficacy and safety profile and cost effectiveness.
About the Report
GlobalDatas new report, "Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018", is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the global osteoarthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.